- Projects & figures
- News & Events
- Managing your project
- About ERC
Effective treatment for obesity remains a challenge and the only intervention proven to maintain weight loss is bariatric surgery. Intrigued by the beneficial effect that this procedure has on the composition of gut microbiota, Dr Fredrik Bäckhed explores the possibility of mimicking these changes to develop a treatment for obesity that won’t require going under the knife.
CRISPR is a widely used molecular biology tool exploiting an immune process discovered in bacteria. Dr David Bikard studies CRISPR in bacterial cells, in conjunction with different DNA repair systems, to create even newer tools. He hopes to gain insight into bacterial genetics, and develop increasingly effective medical treatments.
For the first time ever, a team of scientists and clinicians led by the EU-funded researcher Mickael Tanter has managed to record the brain activity of a premature new-born baby during resting and during an epileptic seizure. Using a non-invasive ultrasound technology, this world premiere is a real game changer for researchers and the medical profession, offering a massive range of applications in neuroimaging and beyond. It is published today in Science Translational Medicine.
Pour la toute première fois, une équipe de scientifiques et des cliniciens dirigée par le chercheur Mickael Tanter, financé par l'UE, a réussi à enregistrer l'activité cérébrale d'un nouveau-né prématuré en phase de repos et lors d'une crise d'épilepsie. À l'aide d'une technologie d'échographie non invasive, cette première mondiale marque un véritable tournant dans le domaine de la recherche et la pratique médicale. Elle offre par ailleurs une vaste gamme d'applications en neuroimagerie et au-delà. L'étude est publiée aujourd'hui dans Science Translational Medicine.
Ole Kamstrup, MD., MSc., is a pensioner and lives north of Copenhagen in Denmark. He has been diagnosed with Parkinson's disease ten years ago. Since 2013, Mr Kamstrup has been in contact with Professor Deniz Kirik, a neuroscientist at Lund University in Sweden. Professor Kirik, who was awarded an ERC Starting Grant in 2009, develops new therapies for Parkinson’s disease, using viral vectors to deliver therapeutic genes to the brain. An ERC Proof of Concept grant enabled him to start carrying out a market evaluation and writing a business plan for the promising therapy.
Originally published in March 2017 as part of the multimedia campaign "ERC - 10 years – 10 portraits."
Cardiovascular diseases (CVD) are a major cause of morbidity and mortality in Europe. Prevention relies on measuring traditional risk factors such as age, gender, hypertension, diabetes, hypercholesterolemia and smoking. However, many individuals, apparently at low-risk, still develop CVD. Improving predictions beyond the traditional risk factors is the challenge undertaken by Prof. Olle Melander.
Through her work with the fruit fly Drosophila santomea, Dr Virginie Orgogozo aims to answer one of the most challenging questions of modern evolutionary biology: how do observable characteristics change between species and yet remain stable in a given species?
While women inherit two X chromosomes, the expressions of one of them is shut down during embryonic development. Men have one X chromosome and one Y chromosome. The switching off of women’s second X chromosome is thought to compensate for the presence of only one X in males versus two in females, to balance for X-linked gene products between the sexes. X-chromosome inactivation is also one of the clearest examples of what epigenetic mechanisms do to our genetic material: the DNA of the genes on the X is still present but not actively expressed or needed. Prof. Edith Heard was awarded ERC grants to understand the intricate processes behind the phenomenon, with unexpected results that changed the way gene regulation is now looked at.
ERC grantee Professor Deniz Kirik's spin-off company will join forces with Skåne Regional Council in southern Sweden to build a specialised hospital and a state-of-the-art gene therapy centre, the parties announced on 8 October. The new facilities are expected to be operational by 2020. They will provide researchers unique opportunities for clinical trials, while patients will gain access to the latest treatment methods for Parkinson’s disease and other illnesses.
In 2012, 2.8 million people in the EU were diagnosed with cancer. It is the second most common cause of death in the Union – three out of 10 deaths for men, and two out of 10 deaths for women – a figure that is expected to rise due to the ageing European population. Dr Danijela Matic Vignjevic’s STARLIN project is using ERC funding to understand how normal cells become cancerous and spread.